1905(a)(29) Medication-Assisted Treatment (MAT)

1905(a)(29) X MAT as described and limited in Supplement 2 to Attachment 3.1-A.

ATTACHMENT 3.1-A identifies the medical and remedial services provided to the categorically needy.

TN No: <u>21-0003</u> Supersedes TN: <u>NEW</u> Approval Date: June 11, 2021

1905(a)(29) Medication-Assisted Treatment (MAT; continued)

i. General Assurance

MAT is covered under the Medicaid state plan for all Medicaid beneficiaries who meet the medical necessity criteria for receipt of the service for the period beginning October 1, 2020 and ending September 30, 2025.

ii. Assurances

- a) The state assures coverage of Naltrexone, Buprenorphine, and Methadone and all of the forms of these drugs for MAT that are approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262).
- b) The state assures that Methadone for MAT is provided by Opioid Treatment Programs that meet the requirements in 42 C.F.R. Part 8.
- c) The state assures coverage for all formulations of MAT drugs and biologicals for OUD that are approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C 262).

iii. Service Package

From October 1, 2020, through September 30, 2025, the state assures that MAT to treat OUD as defined at section 1905(ee)(1) of the Social Security Act (the Act) is covered exclusively under section 1905(a)(29) of the Act.

The state covers the following counseling services and behavioral health therapies as part of MAT.

a) & b)

| Service | Service Description | Qualified Providers |
|--|--|--|
| Medication Administration - MAT for OUD | Services include oral or injectable medications to treat opioid use disorders administered by medical personnel to a recipient, the assessment and documentation of medication compliance, and the assessment and documentation of medication effectiveness and any side effects. | Licensed physicians Licensed Physician Assistants Advanced Practice Registered Nurse Registered Nurses Licensed Practical Nurses |
| Pharmacological Management – MAT for OUD | A type of medical service furnished to a recipient experiencing an opioid use disorder for the purposes of assessing the need for pharmacotherapy, prescribing appropriate medications, and directly monitoring the recipient's response to medication, including documenting medication compliance, assessing and documenting side effects, and evaluating and documenting the effectiveness of the medication. | Licensed physicians Licensed physician assistants Advanced practice registered Nurses |

TN No: 21-0003 Approval Date: Effective Date: October 1, 2020

Supersedes TN: <u>NEW</u>

1905(a)(29) Medication-Assisted Treatment (MAT; continued)

| Individual and Group Therapy – MAT for OUD | Generally, helps patients identify treatment goals and potential solutions to problems that cause emotional stress; seeks to restore communication and coping skills; strengthens self-esteem; and promotes behavior change and optimal mental health. | Community Behavioral Health Service Provider Psychologist Mental Health Professional Licensed Mental Health Professional |
|---|---|--|
| Therapeutic Behavioral Services – MAT for OUD | Include the teaching of knowledge, attitudinal, and skills-based competencies designed to restore functioning for recipients with an OUD and support community living; counseling focused on functional improvement, recovery and relapse prevention; encouraging and coaching. | Community behavioral health services provider Psychologist Mental health professional Licensed Mental Health Professional |

c) Please include a brief summary of the qualifications for each practitioner or provider entity that the state requires. Include any licensure, certification, registration, education, experience, training, and supervisory arrangements that the state requires.

<u>Physician</u> – is a physician licensed to practice, and in good standing, in the State of Alaska with a current federal waiver to dispense narcotic drugs for narcotic treatment (as per 21 U.S.C. 823(g)(2)), current registration or exemption to dispense dangerous drugs as per state law, maintains a DATA waiver as required by federal law and who, as applicable, is employed by or contracted with a certified OTP in the state.

<u>Physician's Assistant (PA)</u> - is licensed to practice, and in good standing, in the State of Alaska, maintains a DATA waiver as required by federal law, and operates within the scope of their collaborative practice agreement with a licensed physician, and who, as applicable, is employed by or contracted with a certified OTP in the state.

Advanced Practice Registered Nurse (APRN) – is licensed to practice, and in good standing, in the State of Alaska, maintains a DATA waiver as required by federal law, and has independent prescriptive authority and who, as applicable, is employed by or contracted with a certified OTP in the state. When APRNs do not have independent prescriptive authority, the APRN operates within the scope of their collaborative practice agreement with a licensed physician.

<u>OTP Exempt MAT Provider</u> – a midlevel practitioner, who when granted an exemption from SAMHSA, can operate independently, i.e., without the supervision of a medical director or a program physician, perform the medical director or physician functions in an OTP based on the Federal opioid treatment standards under 42 C.F.R. 8.12.

<u>Registered Nurse</u> (R.N.) – is licensed to practice, and in good standing, in the State of Alaska and operates within their scope of practice and under the supervision of the prescribing provider;

TN No: 21-0003 Approval Date: Effective Date: October 1, 2020

1905(a)(29) Medication-Assisted Treatment (MAT; continued)

<u>Licensed Practical Nurse</u> (L.P.N.) - is licensed to practice, and in good standing, in the State of Alaska and operates within their scope of practice and under the supervision of the prescribing provider;

Community Behavioral Health Services Provider – a community-based service agency, approved by the department and enrolled in Alaska Medicaid, employing individual rendering behavioral health service providers included in this section. In addition to general conditions for Medicaid participation, including a business license, Medicaid provider agreement, and National Provider Identifier (NPI), CBHS providers must (1) hold a certificate of current grant award issued through the Division of Behavioral Health, (2) hold a certificate of department approval through the Division of Behavioral Health, and (3) ensure their agency and staff, including contractors, sub-contractors, and other vendors meet all other applicable federal and state licensing or certification requirements;

<u>Psychologist – an individual</u> who holds an active license to practice as a psychologist in the State of Alaska, is in good standing, and provides services within scope of practice as defined by state law;

<u>Mental Health Professional -</u> an individual who is working for an enrolled community behavioral health services provider who has a master's degree or more advanced degree in psychology, counseling, child guidance, community mental health, marriage and family therapy, social work, or nursing, is performing community behavioral health services that are within that individual's field of expertise and working under the supervision of a licensed professional in this section; and

<u>Licensed Mental Health Professional</u> - an individual with an active license to practice, and in good standing, as a marital and family therapist, clinical social worker, professional counselor, or psychologist, issued by the State of Alaska.

TN No: <u>21-0003</u> Approval Date: Effective Date: <u>October 1, 2020</u>

1905(a)(29) Medication-Assisted Treatment (MAT; continued)

| iv. | Utilization | Contro | ls |
|-----|-------------|--------|----|
|-----|-------------|--------|----|

| | The state has drug utilization controls in place. (Check each of the following that |
|--------|---|
| apply) | |
| | ☐ Generic first policy |
| | Preferred drug lists |
| | |
| | Quantity limits |
| | |

The state does not have drug utilization controls in place.

v. Limitations

Describe the state's limitations on amount, duration, and scope of MAT drugs, biologicals, and counseling and behavioral therapies related to MAT.

All service limitations may be exceeded with prior authorization based on medical necessity.

- a) MAT Pharmaceuticals are drugs dispensed only upon prescription and approved by the FDA for safety and effectiveness, or licensed as safe, pure, and potent. The state maintains a preferred drug list. Limitations on amount, duration, and scope are based on clinical necessity.
- b) One medical evaluation of a recipient in an opioid use disorder treatment program per admission for that opioid use disorder treatment program including (A) consultation and referral; (B) verification of one year of addiction; and (C) establishing dosage for methadone or another agonist or other agonist or partial agonist.

PRA Disclosure Statement - This information is being collected to assist the Centers for Medicare & Medicaid Services in implementing section 1006(b) of the SUPPORT for Patients and Communities Act (P.L. 115-271) enacted on October 24, 2018. Section 1006(b) requires state Medicaid plans to provide coverage of Medication-Assisted Treatment (MAT) for all Medicaid enrollees as a mandatory Medicaid state plan benefit for the period beginning October 1, 2020, and ending September 30, 2025. Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 60). Public burden for all of the collection of information requirements under this control number is estimated to take about 80 hours per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN No: 21-0003 Approval Date: Effective Date: October 1, 2020

Supersedes TN: NEW